Literature DB >> 22180452

Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals.

Eunkyung Kauh1, Lori Mixson, Marie-Pierre Malice, Sofie Mesens, Steven Ramael, Joanne Burke, Tom Reynders, Kristien Van Dyck, Chan Beals, Elizabeth Rosenberg, Marcella Ruddy.   

Abstract

OBJECTIVE: Use of glucocorticoids for anti-inflammatory efficacy is limited by their side effects. This study examined, in the same individuals, prednisone's acute, dose-dependent effects on inflammation as well as biomarkers of glucose regulation and bone homeostasis.
DESIGN: In this randomized, double-blind, parallel-design trial of healthy adults demonstrating cutaneous allergen-induced hypersensitivity, patients received placebo or prednisone 10, 25 or 60 mg daily for 7 days.
METHODS: Effects on peripheral white blood cell (WBC) count, ex vivo whole blood lipopolysaccharide (LPS)-stimulated TNF-α release and response to cutaneous allergen challenge were assessed concurrently with biomarkers for glucose tolerance and bone turnover.
RESULTS: Differential peripheral WBC counts changed significantly within hours of prednisone administration. Ex vivo, LPS-stimulated TNF-α was significantly reduced by all prednisone doses on days 1 and 7. The late phase cutaneous allergen reaction was significantly reduced with prednisone 60 mg vs placebo on days 1 and 7. Oral glucose tolerance tests revealed significant increases in glycaemic excursion on days 1 and 7, whereas increases in insulin and C-peptide excursions were more notable on day 7 with all doses of prednisone. The bone formation markers osteocalcin, and procollagen I N- and C-terminal peptides decreased significantly on days 1 and 7 vs placebo.
CONCLUSIONS: In healthy young adults after single doses as low as 10 mg, prednisone treatment has significant effects on glucose tolerance and bone formation markers within hours of treatment, in parallel with anti-inflammatory effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180452     DOI: 10.1530/EJE-11-0751

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

1.  Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Authors:  Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; William J Jusko; Panteleimon D Mavroudis; Benjamin D Schwartz; Laurel J Mengle-Gaw; Edward C Smith; Jean K Mah; Michela Guglieri; Yoram Nevo; Nancy Kuntz; Craig M McDonald; Mar Tulinius; Monique M Ryan; Richard Webster; Diana Castro; Richard S Finkel; Andrea L Smith; Lauren P Morgenroth; Adrienne Arrieta; Maya Shimony; Mark Jaros; Phil Shale; John M McCall; Yetrib Hathout; Kanneboyina Nagaraju; John van den Anker; Leanne M Ward; Alexandra Ahmet; Michaelyn R Cornish; Paula R Clemens
Journal:  Pharmacol Res       Date:  2018-09-13       Impact factor: 7.658

Review 2.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 3.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

4.  (Mis)use of Prescribed Stimulants in the Medical Student Community: Motives and Behaviors: A Population-Based Cross-Sectional Study.

Authors:  Guillaume Fond; Martine Gavaret; Christophe Vidal; Lore Brunel; Jean-Pierre Riveline; Jean-Arthur Micoulaud-Franchi; Philippe Domenech
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 5.  Current Status of Research on Osteoporosis after Solid Organ Transplantation: Pathogenesis and Management.

Authors:  Gong-bin Lan; Xu-biao Xie; Long-kai Peng; Lei Liu; Lei Song; He-long Dai
Journal:  Biomed Res Int       Date:  2015-11-15       Impact factor: 3.411

6.  Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.

Authors:  Yetrib Hathout; Laurie S Conklin; Haeri Seol; Heather Gordish-Dressman; Kristy J Brown; Lauren P Morgenroth; Kanneboyina Nagaraju; Christopher R Heier; Jesse M Damsker; John N van den Anker; Erik Henricson; Paula R Clemens; Jean K Mah; Craig McDonald; Eric P Hoffman
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

7.  MicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients.

Authors:  Da Zhi Liu; Boryana Stamova; Shengyong Hu; Bradley P Ander; Glen C Jickling; Xinhua Zhan; Frank R Sharp; Brenda Wong
Journal:  J Neuromuscul Dis       Date:  2015-09-22

8.  Intramembranous ossification and endochondral ossification are impaired differently between glucocorticoid-induced osteoporosis and estrogen deficiency-induced osteoporosis.

Authors:  Hongyang Zhang; Xiaojuan Shi; Long Wang; Xiaojie Li; Chao Zheng; Bo Gao; Xiaolong Xu; Xisheng Lin; Jinpeng Wang; Yangjing Lin; Jun Shi; Qiang Huang; Zhuojing Luo; Liu Yang
Journal:  Sci Rep       Date:  2018-03-01       Impact factor: 4.379

9.  Identification of new biomarker candidates for glucocorticoid induced insulin resistance using literature mining.

Authors:  Wilco Wm Fleuren; Erik Jm Toonen; Stefan Verhoeven; Raoul Frijters; Tim Hulsen; Ton Rullmann; René van Schaik; Jacob de Vlieg; Wynand Alkema
Journal:  BioData Min       Date:  2013-02-04       Impact factor: 2.522

Review 10.  Preventively enteral application of immunoglobulin enriched colostrums milk can modulate postoperative inflammatory response.

Authors:  Klaus Orth; Wolfram Trudo Knoefel; Martijn van Griensven; Christiane Matuschek; Matthias Peiper; Holger Schrumpf; Peter Arne Gerber; Wilfried Budach; Edwin Bölke; Bettina Alexandra Buhren; Matthias Schauer
Journal:  Eur J Med Res       Date:  2013-11-23       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.